Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma

Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma

Ahmed O Kaseb,1 Yinghui Guan,2,* Betul Gok Yavuz,1,* Alexander R Abbas,2 Shan Lu,2 Elshad Hasanov,3 Han Chong Toh,4 Wendy Verret,5 Yulei Wang2 1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Department of Oncolog...

Full description

Bibliographic Details
Main Authors: Kaseb AO, Guan Y, Gok Yavuz B, Abbas AR, Lu S, Hasanov E, Toh HC, Verret W, Wang Y
Format: Article
Language:English
Published: Dove Medical Press 2022-10-01
Series:Journal of Hepatocellular Carcinoma
Subjects:
igf-ctp score
prognostic biomarker
immunotherapy
hcc
Online Access:https://www.dovepress.com/serum-igf-1-scores-and-clinical-outcomes-in-the-phase-iii-imbrave150-s-peer-reviewed-fulltext-article-JHC

Internet

https://www.dovepress.com/serum-igf-1-scores-and-clinical-outcomes-in-the-phase-iii-imbrave150-s-peer-reviewed-fulltext-article-JHC

Similar Items